Prosultiamine hydrochloride | CAS#973-99-9

MedKoo Cat#: 535749 | Name: Prosultiamine hydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Prosultiamine hydrochloride is abiaoctive chemical.

Chemical Structure

Prosultiamine hydrochloride

CAS#973-99-9

Theoretical Analysis

MedKoo Cat#: 535749

Name: Prosultiamine hydrochloride

CAS#: 973-99-9

Chemical Formula: C15H25ClN4O2S2

Exact Mass: 392.1107

Molecular Weight: 392.96

Elemental Analysis: C, 45.85; H, 6.41; Cl, 9.02; N, 14.26; O, 8.14; S, 16.32

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Prosultiamine hydrochloride

IUPAC/Chemical Name

Formamide, N-((4-amino-2-methyl-5-pyrimidinyl)methyl)-N-(4-hydroxy-1-methyl-2-(propyldithio)-1-butenyl)-, monohydrochloride

InChi Key

DURRYBGTQKKQBR-JHGYPSGKSA-N

InChi Code

InChI=1S/C15H24N4O2S2.ClH/c1-4-7-22-23-14(5-6-20)11(2)19(10-21)9-13-8-17-12(3)18-15(13)16;/h8,10,20H,4-7,9H2,1-3H3,(H2,16,17,18);1H/b14-11+;

SMILES Code

O=CN(CC1=CN=C(C)N=C1N)/C(C)=C(SSCCC)\CCO.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 392.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Matsuo T, Miyata Y, Nakamura T, Satoh K, Sakai H. Prosultiamine for treatment of lower urinary tract dysfunction accompanied by human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis. Int J Urol. 2018 Jan;25(1):54-60. doi: 10.1111/iju.13468. Epub 2017 Oct 1. PMID: 28965354. 2: Nishiura Y, Nakamura T, Fukushima N, Nakamura H, Ida H, Aramaki T, Eguchi K. Disulfide-mediated apoptosis of human T-lymphotrophc virus type-I (HTLV-I)-infected cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. Antivir Ther. 2009;14(4):533-42. PMID: 19578238. 3: Nakamura T, Matsuo T, Fukuda T, Yamato S, Yamaguchi K, Kinoshita I, Matsuzaki T, Nishiura Y, Nagasato K, Narita-Masuda T, Nakamura H, Satoh K, Sasaki H, Sakai H, Kawakami A. Efficacy of prosultiamine treatment in patients with human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: results from an open-label clinical trial. BMC Med. 2013 Aug 15;11:182. doi: 10.1186/1741-7015-11-182. PMID: 23945290; PMCID: PMC3826868. 4: Kira J. Therapeutic benefits of an oral vitamin B1 derivative for human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). BMC Med. 2013 Aug 15;11:183. doi: 10.1186/1741-7015-11-183. PMID: 23945332; PMCID: PMC3826871. 5: Oka H, Tsuzuki K, Takebayashi H, Kojima Y, Daimon T, Sakagami M. Olfactory changes after endoscopic sinus surgery in patients with chronic rhinosinusitis. Auris Nasus Larynx. 2013 Oct;40(5):452-7. doi: 10.1016/j.anl.2012.12.001. Epub 2013 Jan 11. PMID: 23312885. 6: Nakashima T, Kidera K, Miyazaki J, Kuratomi Y, Inokuchi A. Smell intensity monitoring using metal oxide semiconductor odor sensors during intravenous olfaction test. Chem Senses. 2006 Jan;31(1):43-7. doi: 10.1093/chemse/bjj004. Epub 2005 Dec 1. PMID: 16322087. 7: Hirakawa K. [Prognosis in olfaction disorders]. Nihon Jibiinkoka Gakkai Kaiho. 2004 Oct;107(10):937-42. Japanese. doi: 10.3950/jibiinkoka.107.937. PMID: 15658010. 8: Saito K, Takahashi M, Fukuta K, Tachibana E, Yoshida J. Recovery of olfactory function after an anterior craniofacial approach. Skull Base Surg. 1999;9(3):201-6. doi: 10.1055/s-2008-1058147. PMID: 17171090; PMCID: PMC1656739. 9: Kasuga Y, Nishimura K, Go H, Nakazaki K, Shimizu S, Kanezawa K, Tanaka M, Oshima T, Morioka I. Severe olfactory and gustatory dysfunctions in a Japanese pediatric patient with coronavirus disease (COVID-19). J Infect Chemother. 2020 Sep 30:S1341-321X(20)30350-0. doi: 10.1016/j.jiac.2020.09.030. Epub ahead of print. PMID: 33039267; PMCID: PMC7526635. 10: Zusho H. Olfactometry in Japan. Rhinology. 1983 Sep;21(3):281-5. PMID: 6635477.